In this video, Lynn Schuchter, MD, Chief, Division of Hematology/Oncology at Penn Medicine reviews the latest advances in the treatment of melanoma, including ipilimumab, nivolumab, AntiPD1 monoclonal antibody MK3475, dabrafenib and trametinib. Penn's Melanoma program has been recognized by the NCI as "outstanding," the highest rating possible for a cancer research program, and one signifying excellence in overall program quality, representation of relevant scientific disciplines, translation of new findings to the clinical setting, conduction of clinical trials, interaction of researchers, and caliber of program members and leadership.
Related Links
Published
April 22, 2015
Created by
BROADCASTMED